drugset / Trial / NCT05421338

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

NCT05421338

Phase 1 Completed 6 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

This trial is intended to examine the basic pharmacokinetics of BI 456906 and total \[14C\]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in (otherwise) healthy male volunteers with normal body weight, overweight or obesity.

Timeline

Start
2022-07-04
Primary completion
2022-11-17
Completion
2022-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Survodutide Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.